MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1695 views | HTML 2121 views | ?
Bo Liu1, Minxiao Yi1, Yang Tang1, Qingxu Liu1, Hong Qiu1, Yanmei Zou1, Ping Peng1, Lu Zhang1, Chunping Hu2, Xianglin Yuan1
1Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
2Department of Statistics, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
Xianglin Yuan, email: [email protected]
Keywords: single nucleotide polymorphism, radiation-induced lung injury, lung cancer, MMP-1, radiotherapy
Received: April 25, 2016 Accepted: September 14, 2016 Published: September 21, 2016
Matrix metalloproteinase-1 (MMP-1) has been implicated in several inflammatory and fibrotic diseases. We hypothesized that genetic variations in the MMP1 promoter region are associated with risk of radiation-induced lung injury (RILI). A cohort of 251 lung cancer patients was genotyped for five single nucleotide polymorphisms in the MMP1 promoter region. We found that rs1144393 AG/GG was strongly correlated with an increased occurrence of grade ≥ 2 RILI (p = 0.002). Additionally, patients with the rs1144393 AG/GG genotypes exhibited higher MMP-1 expression than patients with the AA genotype in lung tissues (n = 28, p = 0.022) and plasma samples (n = 40, p = 0.018). Our results indicated that rs1144393 in the MMP1 promoter region can be a predictor of grade ≥ 2 RILI in lung cancer patients treated with thoracic radiation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.